|
1) 国際頭痛学会・頭痛分類委員会. 国際頭痛分類第2版(ICHD-II, 日本語版). 日本頭痛学会誌. 2004; 31: 1
|
|
|
|
2) World Health Organization. World Health Organization, editor. Geneva, Switzerland, World Health Organization. 2-12-0007. Headache disorder. Fact sheet No. 277, 2004
|
|
|
|
|
|
3) Binder WJ, Brin MF, Blitzer A, et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000; 123: 669
|
|
|
|
|
4) Troost BT. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev Neurother. 2004; 4: 27
|
|
|
|
|
|
5) Mitchell MP, Schaecher K, Cannon HE, et al. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization. J Manag Care Pharm. 2008; 14: 442
|
|
|
|
|
|
6) Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology. 2005; 26: 785
|
|
|
|
|
|
7) Rapoport AM. New acute treatments for headache. Neurol Sci. 2010; 31 Suppl 1: S129
|
|
|
|
|
|
8) Goadsby PJ, Sprenger T. Current practice and future directions in the prevention and acute management of migraine. Lancet Neurol. 2010; 9: 285
|
|
|
|
|
|
9) Suzuki K, Iizuka T, Sakai F. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial. Intern Med. 2007; 46: 959
|
|
|
|
|
10) Silberstein S, Mathew N, Saper J, et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache. 2000; 40: 445
|
|
|
|
|
|
11) Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study. Cephalalgia. 2004; 24: 838
|
|
|
|
|
|
12) Elkind AH, OʼCarroll P, Blumenfeld A, et al. BoNTA-024-026-036 Study Group. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain. 2006; 7: 688
|
|
|
|
|
|
13) Relja M, Poole AC, Schoenen J, et al. European BoNTA Headache Study Group. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia. 2007; 27: 492
|
|
|
|
|
|
14) Aurora SK, Gawel M, Brandes JL, et al. BOTOX North American Episodic Migraine Study Group. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache. 2007; 47: 486
|
|
|
|
|
|
15) Saper JR, Mathew NT, Loder EW, et al; BoNTA-009 Study Group. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med. 2007; 8: 478
|
|
|
|
|
|
16) Naumann M, So Y, Argoff CE, et al. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70: 1707
|
|
|
|
|
|
17) Shuhendler AJ, Lee S, Siu M, et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy. 2009; 29: 784
|
|
|
|
|
|
18) Zubieta JK, Yau WY, Scott DJ, et al. Belief or need？ Accounting for individual variations in the neurochemistry of the placebo effect. Brain Behav Immu. 2006; 20: 15
|
|
|
|
|
|
19) Burstein R, Dodick D, Silberstein S. Migraine prophylaxis with botulinum toxin A is associated with perception of headache. Toxicon. 2009; 54: 624
|
|
|
|
|
|
20) Rollnik JD, Tanneberger O, Schubert M, et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache. 2000; 40: 300
|
|
|
|
|
|
21) Schmitt WJ, Slowey E, Fravi N, et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache. 2001; 41: 658
|
|
|
|
|
|
22) Padberg M, de Bruijn SF, de Haan RJ, et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia. 2004; 24: 675
|
|
|
|
|
|
23) Schulte-Mattler WJ, Krack P. BoNTTH Study Group. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain. 2004; 109: 110
|
|
|
|
|
|
24) Silberstein SD, Göbel H, Jensen R, et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia. 2006; 26: 790
|
|
|
|
|
|
25) Relja M, Telarović S. Botulinum toxin in tension-type headache. J Neurol. 2004; 251 Suppl 1: I12
|
|
|
|
|
|
26) Straube A, Empl M, Ceballos-Baumann A, et al. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache - a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol. 2008; 15: 205
|
|
|
|
|
|
27) Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology. 1996; 47: 871
|
|
|
|
|
|
28) Mathew NT, Frishberg BM, Gawel M, et al; BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache. 2005; 45: 293
|
|
|
|
|
|
29) Dodick DW, Mauskop A, Elkind AH, et al. BOTOX CDH Study Group. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache. 2005; 45: 315
|
|
|
|
|
|
30) Silberstein SD, Stark SR, Lucas SM, et al. BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005; 80: 1126
|
|
|
|
|
|
31) Freitag FG, Diamond S, Diamond M, et al. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache. 2008; 48: 201
|
|
|
|
|
|
32) Aurora SK, Dodick DW, Turkel CC, et al; PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010; 30: 793
|
|
|
|
|
|
33) Diener HC, Dodick DW, Aurora SK, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010; 30: 804
|
|
|
|
|
|
34) Dodick DW, Turkel CC, DeGryse RE, et al; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010; 50: 921
|
|
|
|
|
|
35) Ondo WG, Gollomp S, Galvez-Jimenez N. A pilot study of botulinum toxin A for headache in cervical dystonia. Headache. 2005; 45: 1073
|
|
|
|
|
|
36) Sostak P, Krause P, Förderreuther S, et al. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain. 2007; 8: 236
|
|
|
|
|
|
37) Taylor M, Silva S, Cottrell C. Botulinum toxin type-A (BOTOX) in the treatment of occipital neuralgia: a pilot study. Headache. 2008; 48: 1476
|
|
|
|
|
|
38) Ashkenazi A. Botulinum toxin type a for chronic migraine. Curr Neurol Neurosci Rep. 2010; 10: 140
|
|
|
|
|